Kythera Biopharmaceuticals Presents Positive Magnetic Resonance Imaging (MRI) Results from Phase IIb Study of ATX-101 in the Reduction of Submental Fat or “Double Chin”

KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today presented positive results that found MRI measurements of patients treated with ATX-101 demonstrated a statistically significant reduction in submental fat (SMF), commonly known as double chin, during an oral session at The Aesthetic Meeting 2013, organized by the American Society for Aesthetic Plastic Surgery (ASAPS), April 11-16, New York, NY.